IgG1-3 MuSK Antibodies Inhibit AChR Cluster Formation, Restored by SHP2 Inhibitor, Despite Normal MuSK, DOK7, or AChR Subunit Phosphorylation.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
06
04
2023
accepted:
07
06
2023
medline:
17
8
2023
pubmed:
16
8
2023
entrez:
15
8
2023
Statut:
epublish
Résumé
Up to 50% of patients with myasthenia gravis (MG) without acetylcholine receptor antibodies (AChR-Abs) have antibodies to muscle-specific kinase (MuSK). Most MuSK antibodies (MuSK-Abs) are IgG4 and inhibit agrin-induced MuSK phosphorylation, leading to impaired clustering of AChRs at the developing or mature neuromuscular junction. However, IgG1-3 MuSK-Abs also exist in MuSK-MG patients, and their potential mechanisms have not been explored fully. C2C12 myotubes were exposed to MuSK-MG plasma IgG1-3 or IgG4, with or without purified agrin. MuSK, Downstream of Kinase 7 (DOK7), and βAChR were immunoprecipitated and their phosphorylation levels identified by immunoblotting. Agrin and agrin-independent AChR clusters were measured by immunofluorescence and AChR numbers by binding of IgG1-3 MuSK-Abs impaired AChR clustering without inhibiting agrin-induced MuSK phosphorylation. Moreover, the well-established pathway initiated by MuSK through DOK7, resulting in βAChR phosphorylation, was not impaired by MuSK-IgG1-3 and was agrin-independent. Nevertheless, the AChR clusters did not form, and both the number of AChR microclusters that precede full cluster formation and the myotube surface AChRs were reduced. Transcriptomic analysis did not throw light on the pathways involved. However, the SHP2 inhibitor, NSC-87877, increased the number of microclusters and led to fully formed AChR clusters. MuSK-IgG1-3 is pathogenic but seems to act through a noncanonical pathway. Further studies should throw light on the mechanisms involved at the neuromuscular junction.
Sections du résumé
BACKGROUND AND OBJECTIVES
Up to 50% of patients with myasthenia gravis (MG) without acetylcholine receptor antibodies (AChR-Abs) have antibodies to muscle-specific kinase (MuSK). Most MuSK antibodies (MuSK-Abs) are IgG4 and inhibit agrin-induced MuSK phosphorylation, leading to impaired clustering of AChRs at the developing or mature neuromuscular junction. However, IgG1-3 MuSK-Abs also exist in MuSK-MG patients, and their potential mechanisms have not been explored fully.
METHODS
C2C12 myotubes were exposed to MuSK-MG plasma IgG1-3 or IgG4, with or without purified agrin. MuSK, Downstream of Kinase 7 (DOK7), and βAChR were immunoprecipitated and their phosphorylation levels identified by immunoblotting. Agrin and agrin-independent AChR clusters were measured by immunofluorescence and AChR numbers by binding of
RESULTS
IgG1-3 MuSK-Abs impaired AChR clustering without inhibiting agrin-induced MuSK phosphorylation. Moreover, the well-established pathway initiated by MuSK through DOK7, resulting in βAChR phosphorylation, was not impaired by MuSK-IgG1-3 and was agrin-independent. Nevertheless, the AChR clusters did not form, and both the number of AChR microclusters that precede full cluster formation and the myotube surface AChRs were reduced. Transcriptomic analysis did not throw light on the pathways involved. However, the SHP2 inhibitor, NSC-87877, increased the number of microclusters and led to fully formed AChR clusters.
DISCUSSION
MuSK-IgG1-3 is pathogenic but seems to act through a noncanonical pathway. Further studies should throw light on the mechanisms involved at the neuromuscular junction.
Identifiants
pubmed: 37582613
pii: 10/6/e200147
doi: 10.1212/NXI.0000000000200147
pmc: PMC10427144
pii:
doi:
Substances chimiques
Agrin
0
DOK7 protein, human
0
Immunoglobulin G
0
Muscle Proteins
0
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Receptors, Cholinergic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
J Neurosci. 2008 Feb 13;28(7):1688-96
pubmed: 18272689
Brain. 2014 Aug;137(Pt 8):2178-92
pubmed: 24951641
Cell. 1996 May 17;85(4):501-12
pubmed: 8653786
Neuron. 2008 Oct 23;60(2):285-97
pubmed: 18957220
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20783-8
pubmed: 24297891
J Biol Chem. 2008 Aug 1;283(31):21668-75
pubmed: 18541538
Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18812-7
pubmed: 19020093
Dev Neurobiol. 2007 Nov;67(13):1789-801
pubmed: 17659592
J Autoimmun. 2017 Feb;77:104-115
pubmed: 27965060
Neurol Neuroimmunol Neuroinflamm. 2019 Feb 21;6(3):e547
pubmed: 30882021
Int J Mol Sci. 2011;12(12):8924-46
pubmed: 22272112
Ann Clin Transl Neurol. 2019 Dec;6(12):2395-2402
pubmed: 31725979
Neurosci Lett. 2020 Aug 10;733:135054
pubmed: 32428606
PLoS One. 2013 Nov 07;8(11):e80695
pubmed: 24244707
Brain. 2008 Jul;131(Pt 7):1940-52
pubmed: 18515870
Neurol Neuroimmunol Neuroinflamm. 2019 Dec 12;7(1):
pubmed: 31831571
Hum Mutat. 2020 Mar;41(3):619-631
pubmed: 31765060
JCI Insight. 2019 Jun 20;4(12):
pubmed: 31217355
Front Mol Neurosci. 2020 Sep 02;13:159
pubmed: 32982689
Front Mol Neurosci. 2022 Mar 15;15:780659
pubmed: 35370548
J Neuroimmunol. 2016 Jun 15;295-296:84-92
pubmed: 27235354
Brain. 2003 Oct;126(Pt 10):2304-11
pubmed: 12821509
Mol Brain. 2012 Feb 06;5:7
pubmed: 22309736
BMC Neurosci. 2009 Jul 16;10:80
pubmed: 19604411
Cell Signal. 2023 Apr;104:110584
pubmed: 36608736
Mol Cell Neurosci. 2005 Mar;28(3):403-16
pubmed: 15737732
J Cell Sci. 2012 Mar 15;125(Pt 6):1531-43
pubmed: 22328506
Neurosci Lett. 2020 Jul 13;731:135014
pubmed: 32353380
Sci Signal. 2016 Sep 06;9(444):ra87
pubmed: 27601729
Neuron. 1991 Jun;6(6):869-78
pubmed: 1711347
Proc Natl Acad Sci U S A. 2021 Mar 30;118(13):
pubmed: 33753489
Int J Mol Sci. 2018 Feb 06;19(2):
pubmed: 29415504